- Home
- OBE vs BBNX Comparison
OBE vs BBNX Comparison
Compare OBE & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | BBNX |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | Canada | United States |
| Employees | N/A | 423 |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.9M | 493.1M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | OBE | BBNX |
|---|---|---|
| Price | $13.16 | $10.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $10.00 | ★ $23.80 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | $20.21 | $34.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.88 | $8.80 |
| 52 Week High | $13.75 | $32.71 |
Technical Indicators
Market Signals| Indicator | OBE | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 78.84 | 42.21 |
| Support Level | $5.57 | $9.36 |
| Resistance Level | N/A | $11.92 |
| Average True Range (ATR) | 0.70 | 1.11 |
| MACD | 0.34 | -0.02 |
| Stochastic Oscillator | 87.44 | 34.62 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.